PXL770
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adrenomyeloneuropathy
Conditions
Adrenomyeloneuropathy
Trial Timeline
Sep 1, 2023 → Sep 1, 2024
NCT ID
NCT05146284About PXL770
PXL770 is a phase 2 stage product being developed by Poxel for Adrenomyeloneuropathy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05146284. Target conditions include Adrenomyeloneuropathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05146284 | Phase 2 | Withdrawn |
| NCT05441904 | Phase 1 | Completed |
Competing Products
1 competing product in Adrenomyeloneuropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK0214 | Viking Therapeutics | Phase 1 | 28 |